Loading…
AnaptysBio, Inc. is projected to rise to $83.62 by 2027, a +45% move from its current price of $57.69. ANAB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean neutral.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $55.71 | $57.67 | $59.70 | -0.03% |
| May 30 | $54.91 | $57.66 | $60.55 | -0.06% |
| May 31 | $54.29 | $57.64 | $61.20 | -0.08% |
| Jun 1 | $53.78 | $57.63 | $61.75 | -0.11% |
| Jun 2 | $53.33 | $57.61 | $62.24 | -0.14% |
| Jun 3 | $52.92 | $57.59 | $62.68 | -0.17% |
| Jun 4 | $52.55 | $57.58 | $63.09 | -0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $52.55 | $57.58 | $63.09 | -0.19% |
| Week 2 | $50.49 | $57.47 | $65.40 | -0.39% |
| Week 3 | $48.95 | $57.35 | $67.20 | -0.58% |
| Week 4 | $47.67 | $57.24 | $68.73 | -0.78% |
| Week 5 | $46.57 | $57.13 | $70.09 | -0.97% |
| Week 6 | $45.58 | $57.02 | $71.33 | -1.16% |
| Week 7 | $44.68 | $56.91 | $72.48 | -1.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. Its portfolio includes Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc.
and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
ANAB is a biotechnology stock listed with a current price of $59.71 and a market cap of $1.74B, ranking at 2109. The stock sits in the healthcare sector, with a diversified antibody program portfolio under development across multiple clinical stages.
A major floor 47.2% below — a decisive break under it would weaken the trend.
The nearest floor, 22.7% below — buyers have tended to step in here.
The nearest ceiling, 21.0% above — a clean break opens room to run.
A major ceiling 43.1% above — clearing it would confirm fresh momentum.
Key ANAB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ANAB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $59.13 | Sell | $58.93 | Sell |
| MA 10 | $60.22 | Sell | $60.25 | Sell |
| MA 20 | $63.66 | Sell | $60.30 | Sell |
| MA 50 | $53.02 | Buy | $54.52 | Buy |
| MA 100 | $43.83 | Buy | $46.59 | Buy |
| MA 200 | $32.79 | Buy | $37.25 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.52 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -111.38 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -1.61 | Sell |
| ROC (12) | -16.79 | Sell |
| Bollinger %B (20,2) | 0.12 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.78 | Buy |
| Awesome (5,34) | 0.53 | Buy |
| Ultimate (7,14,28) | 26.80 | Buy |
| Momentum (10) | -7.89 | Sell |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 58.15 | Sell |
| ADX (14) | 21.25 | Sell |
| ATR (14) | 1.63 | Info |
Technical momentum and near-term setup show a bullish tilt with a current sentiment labeled BULLISH. The RSI14 sits at 50, while the 50-day moving average is $52.44 and the 200-day moving average is $32.35. Support is identified at $44.60 and resistance at $69.78, framing a constructive near-term range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $28.80 | $57.69 | $87.51 | 0% | Neutral | |
| $64.61 | $83.62 | $115.60 | +45% | Bullish | |
| $69.94 | $93.78 | $135.40 | +63% | Bullish | |
| $74.77 | $103.29 | $154.33 | +79% | Bullish | |
| $86.08 | $122.14 | $187.80 | +112% | Bullish | |
| $92.34 | $134.27 | $211.70 | +133% | Bullish | |
| $113.28 | $168.56 | $271.79 | +192% | Bullish | |
| $143.84 | $218.74 | $359.94 | +279% | Bullish | |
| $153.75 | $238.72 | $400.21 | +314% | Bullish | |
| $171.27 | $271.30 | $462.74 | +370% | Bullish | |
| $256.65 | $445.92 | $817.36 | +673% | Bullish | |
| $448.31 | $919.04 | $1,868.95 | +14.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $28.80 | $57.69 | $68.14 | +0.00% |
| June 2026 | $48.45 | $57.23 | $69.45 | -0.80% |
| July 2026 | $47.11 | $56.24 | $69.41 | -1.72% |
| August 2026 | $48.67 | $58.59 | $73.25 | +4.18% |
| September 2026 | $49.99 | $60.61 | $76.58 | +3.45% |
| October 2026 | $49.63 | $60.56 | $77.24 | -0.08% |
| November 2026 | $51.20 | $62.82 | $80.79 | +3.73% |
| December 2026 | $54.73 | $67.53 | $87.51 | +7.48% |
Click any year to see its month-by-month ANAB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ANAB price prediction for 2026 points to an average of $57.69 (low $28.80, high $87.51) — a potential gain of 0% on today's $57.69. A consolidation phase looks the most probable path here.
In 2027, ANAB is projected to trade between $64.61 and $115.60, averaging $83.62 — a potential gain of +45% from today's $57.69. That is up +45% on the projected 2026 average. Momentum favours further upside here.
AnaptysBio, Inc.'s 2028 outlook centres on $93.78, within a $69.94 to $135.40 range. That is up +12% on the projected 2027 average. That marks a +63% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ANAB could reach as high as $154.33, with a base case around $103.29 and support toward $74.77 — roughly +79% from $57.69. Momentum favours further upside here.
Expect ANAB to range from $86.08 to $187.80 through 2030. The $122.14 average target implies a +112% move from current prices. That is up +18% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ANAB price prediction for 2031 points to an average of $134.27 (low $92.34, high $211.70) — a potential gain of +133% on today's $57.69. Momentum favours further upside here.
In 2032, ANAB is projected to trade between $113.28 and $271.79, averaging $168.56 — a potential gain of +192% from today's $57.69. That is up +26% on the projected 2031 average. Buyers look set to stay in control over this stretch.
AnaptysBio, Inc.'s 2033 outlook centres on $218.74, within a $143.84 to $359.94 range. That is up +30% on the projected 2032 average. That marks a +279% change versus current levels. Momentum favours further upside here.
By 2034, ANAB could reach as high as $400.21, with a base case around $238.72 and support toward $153.75 — roughly +314% from $57.69. Buyers look set to stay in control over this stretch.
Expect ANAB to range from $171.27 to $462.74 through 2035. The $271.30 average target implies a +370% move from current prices. That is up +14% on the projected 2034 average. Momentum favours further upside here.
The ANAB price prediction for 2040 points to an average of $445.92 (low $256.65, high $817.36) — a potential gain of +673% on today's $57.69. Buyers look set to stay in control over this stretch.
In 2050, ANAB is projected to trade between $448.31 and $1,868.95, averaging $919.04 — a potential gain of +14.9x from today's $57.69. That is up +106% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ANAB today (≈ 17.334027 ANAB) could be worth
$15,930.72
+$14,930.72 (+1493%) by 2050 · US Dollar
Based on the average projected ANAB price of $919.04 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ANABwould be worth at today's price.
$1,000 invested in ANAB on May 27, 2025 (≈ 74.515648 ANAB) would be worth
$4,298.81
+$3,298.81 (+329.9%) today · 4.30× · US Dollar
Based on a ANAB entry price of $13.42 vs. today's $57.69.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $60.08 | $960.22 | -4.0% |
| 1 month ago | $66.59 | $866.35 | -13.4% |
| 3 months ago | $37.41 | $1,542.24 | +54.2% |
| 6 months ago | $27.77 | $2,077.67 | +107.8% |
| 1 year ago | $13.42 | $4,298.81 | +329.9% |
| All time (5.0y) ago | $15.95 | $3,616.17 | +261.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ANAB forecast.
Our base-case forecast reaches $120.00 around 2030.
Implied market cap at $120.00: $3.49B
The multi-year forecast paints a rising path for ANAB, with the 2026 average price at $59.71 and a neutral sentiment for that year. By 2030, the average price is projected to $122.84 with an ROI of 105.7 and a bullish sentiment; by 2040, the average price is $445.68 with an ROI of 646.4 and a bullish sentiment; by 2050, the average price is $908.46 with an ROI of 1421.5 and a bullish sentiment. The max targets show substantial upside into the billions for later years, with the 2050 maximum at $1,880.19.
The forecast underlines ongoing bullish momentum across the long horizon, though these figures are estimates, not guarantees, and depend on clinical and market developments as well as broader conditions. Drivers noted in the data include ongoing antibody programs and collaborations that may progress toward milestones.
Tap a question to reveal the answer.
Avg $122.84; min $85.71; max $190.86; ROI 105.7; sentiment BULLISH.
The 2026 forecast is NEUTRAL; longer-term outlook is BULLISH with averages rising to $122.84 by 2030 and $908.46 by 2050, and ROIs reaching 105.7 and 1421.5 respectively. These are estimates, not guarantees.
Yes—the 2050 max is $1,880.19, which exceeds $1,000.
Current price is $59.71 and market cap is $1.74B.
Low $47.10; High $75.69.
AnaptysBio, Inc. Community Discussion
0Share your AnaptysBio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.